Best treatments for parkinson disease
18 products may treat parkinson disease, spanning FDA drug classes such as nonergot dopamine agonist, monoamine oxidase inhibitor, anticholinergic. The current highest-rated option is mirapex er. Ranked below by our independent recall-safety rating (rated where FDA data exists) — not medical advice; always consult a professional.
Quick answer: Of the 18 drugs we list for parkinson disease, 8 are available as lower-cost generics, spanning classes such as nonergot dopamine agonist, monoamine oxidase inhibitor, anticholinergic. They’re ranked by each drug’s FDA recall-safety record — not clinical effectiveness for parkinson disease — so confirm the right choice with your prescriber.
Understanding parkinson disease
Parkinson's disease is a progressive movement disorder that develops when nerve cells in the brain no longer make enough of a chemical called dopamine. In a brain region called the substantia nigra, these dopamine-producing cells slowly die, and without enough dopamine the brain cannot properly control muscle movement. Symptoms usually appear gradually and can affect one or both sides of the body. The main motor symptoms are resting tremor (trembling of the hands, arms, legs, jaw, or face), slowness of movement, stiffness or rigidity of the arms, legs, and trunk, and poor balance and coordination. Many people also have non-motor symptoms, some appearing early, such as reduced sense of smell, constipation, sleep problems, depression, and anxiety; cognitive changes can occur as the disease progresses. There is no single test for Parkinson's disease; doctors diagnose it from medical history and a neurological examination, and other tests may be used to rule out conditions with similar symptoms. There is no cure, but medicines, deep brain stimulation surgery, physical and occupational therapy, and exercise can help control symptoms. This is general information, not medical advice.
First-line treatment
For motor symptoms in early Parkinson's disease, the American Academy of Neurology's 2021 practice guideline recommends levodopa as the initial preferred medication, because studies show it provides greater improvement in motor symptoms than dopamine agonists or MAO-B inhibitors. Levodopa works by replenishing dopamine in the brain. The guideline notes that levodopa is more likely than dopamine agonists to cause dyskinesia (involuntary movements) over time, but that severe or disabling dyskinesia in the first few years is uncommon. Dopamine agonists, by contrast, carry a higher risk of impulse-control problems and are possibly more likely to cause hallucinations. Because of these trade-offs, the guideline advises clinicians to counsel each person on the benefits and risks of levodopa, dopamine agonists, and MAO-B inhibitors, and to individualize the choice based on the person's disease characteristics and circumstances. This is general information, not medical advice.
Top-rated picks for parkinson disease: 1. Mirapex ER · 2. Neupro · 3. Ongentys
| # | Drug | Rating | Type | Form | Class | Generic? | Pharmacy pays | |
|---|---|---|---|---|---|---|---|---|
| 1 | 72/100 | Prescription | Tablet | Nonergot Dopamine Agonist | Generic | $2 | View → | |
| 2 | 70/100 | Prescription | Patch | Nonergot Dopamine Agonist | No data | — | View → | |
| 3 | 70/100 | Prescription | Capsule | — | No data | — | View → | |
| 4 | 56/100 | Prescription | Tablet | Monoamine Oxidase Inhibitor | Generic | $30 | View → | |
| 5 | Not yet rated | Prescription | Injectable | — | No data | — | View → | |
| 6 | Not yet rated | Prescription | Injectable | Anticholinergic | No data | — | View → | |
| 7 | Not yet rated | Prescription | Tablet | Catechol-O-Methyltransferase Inhibitor | Generic | $11 | View → | |
| 8 | Not yet rated | Prescription | Patch | Monoamine Oxidase Inhibitor | Generic | $20 | View → | |
| 9 | Not yet rated | Prescription | Capsule | Influenza A M2 Protein Inhibitor | Generic | $5 | View → | |
| 10 | Not yet rated | Prescription | Capsule | Aromatic Amino Acid | No data | — | View → |
Narrow by drug class
Explore the class hubs: monoamine oxidase inhibitor · nonergot dopamine agonist
Full ranking · 18 treatments
mirapex er
PrescriptionFDA-sourced
Mirapex ER (Pramipexole Dihydrochloride) is a nonergot dopamine agonist used to treat Depressive Disorder, Parkinson Disease.
Pharmacy pays
From ~$1.24/30· 8 formsneupro
PrescriptionFDA-sourced
Neupro (Rotigotine) is a nonergot dopamine agonist used to treat Parkinson Disease, Restless Legs Syndrome.
Price varies
ongentys
PrescriptionFDA-sourced
Ongentys (Opicapone) is a medication used to treat Parkinson Disease.
Price varies
azilect
PrescriptionFDA-sourced
Azilect (Rasagiline Mesylate) is a monoamine oxidase inhibitor used to treat Parkinson Disease.
Pharmacy pays
From ~$28.05/30· 2 forms Save up to 42% in classapokyn
PrescriptionFDA-sourced
Apokyn (Apomorphine Hydrochloride) is a medication used to treat Parkinson Disease.
Price varies
benztropine mesylate
PrescriptionFDA-sourced
Benztropine Mesylate is an anticholinergic used to treat Drug-Induced Abnormalities, Parkinson Disease.
Price varies
Frequently asked
- What treats parkinson disease?
- Our catalog lists 18 products that may treat parkinson disease, based on NIH RxClass (MED-RT “may treat”) drug-classification data — not the verbatim FDA label. They're rated where FDA recall-safety data exists; the current top-rated option is mirapex er.
- What is the best-rated treatment for parkinson disease?
- By our independent recall-safety rating — not an efficacy measure — mirapex er ranks highest among the products we list for parkinson disease. Always consult a professional.
- How are these treatments ranked?
- By our independent score, currently based on FDA regulatory recall-safety data (the methodology blends additional sources as they come online). See the How we rate page.
- What types of drugs treat parkinson disease?
- Treatments for parkinson disease span FDA drug classes including nonergot dopamine agonist, monoamine oxidase inhibitor, anticholinergic, antihistamine, catechol-o-methyltransferase inhibitor. Compare every option side by side, ranked by independent rating, above.
Treatment associations are derived from NIH RxClass (MED-RT “may treat”) drug-classification data — not the verbatim FDA label. This is general reference, not medical advice — always consult a licensed professional.
Sources
The clinical overview above is written from these authoritative public-health and medical-society sources, independently reviewed against each.
- Parkinson's Disease (MedlinePlus, U.S. National Library of Medicine) ↗
- Parkinson disease: MedlinePlus Medical Encyclopedia (U.S. National Library of Medicine) ↗
- Parkinson's disease explained (NIH MedlinePlus Magazine, U.S. National Library of Medicine) ↗
- Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary (American Academy of Neurology, 2021) ↗